Shockwave Medical (SWAV) Stock Price, News & Analysis

Company Overview

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

Key Stats

• Today's Range: $334.75 to $334.75
• 50-Day Range: $328.87 to $334.83
• 52-Week Range: $157.00 to $334.90
• Volume: N/A
• Average Volume: 968,088 shs
• Market Capitalization: $12.57 billion
• P/E Ratio: 78.21
• Dividend Yield: N/A
• Price Target: $320.50
• Consensus Rating: Hold

Shockwave Medical Stock Analysis - MarketRank™

Shockwave Medical scored higher than 40% of companies evaluated by MarketBeat, and ranked 599th out of 957 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Hold

Consensus Rating

Shockwave Medical has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on 1 buy rating, 9 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Shockwave Medical has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 21.98%

Earnings Growth

Earnings for Shockwave Medical are expected to grow by 21.98% in the coming year, from $5.05 to $6.16 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Shockwave Medical is 78.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 104.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shockwave Medical is 78.21, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 63.13.

Price to Earnings Growth Ratio

Shockwave Medical has a PEG Ratio of 2.43. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Shockwave Medical has a P/B Ratio of 16.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SWAV.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Shockwave Medical does not currently pay a dividend.

Dividend Growth

Shockwave Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.55

Short Interest

There is no current short interest data available for SWAV.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shockwave Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.40% of the stock of Shockwave Medical is held by insiders.

Percentage Held by Institutions

95.35% of the stock of Shockwave Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SWAV Stock Analysis - Frequently Asked Questions

How were Shockwave Medical's earnings last quarter?

Shockwave Medical, Inc. (NASDAQ:SWAV) posted its earnings results on Monday, May, 6th. The company reported $1.44 EPS for the quarter, beating the consensus estimate of $0.99 by $0.45. The business's revenue was up 35.8% compared to the same quarter last year.

When did Shockwave Medical IPO?

Shockwave Medical (SWAV) raised $75 million in an initial public offering (IPO) on Thursday, March 7th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What other stocks do shareholders of Shockwave Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Shockwave Medical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/06/2024
• Today: 2/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SWAV
• CUSIP: N/A
• CIK: 1642545
• Web: www.shockwavemedical.com
• Phone: (877) 775-4846
• Fax: N/A
• Employees: 1,468
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $320.50
• High Stock Price Target: $368.00
• Low Stock Price Target: $210.00
• Potential Upside/Downside: -4.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.10
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $4.28
• Trailing P/E Ratio: 78.21
• Forward P/E Ratio: 66.29
• P/E Growth: 2.43
• Net Income: $147.28 million
• Net Margins: 20.75%
• Pretax Margin: 23.29%
• Return on Equity: 24.79%
• Return on Assets: 11.95%

Debt

• Debt-to-Equity Ratio: 0.97
• Current Ratio: 13.81
• Quick Ratio: 12.61

Sales & Book Value

• Annual Sales: $787.97 million
• Price / Sales: 15.95
• Cash Flow: $4.31 per share
• Price / Cash Flow: 77.61
• Book Value: $20.02 per share
• Price / Book: 16.72

Miscellaneous

• Outstanding Shares: 37,544,000
• Free Float: 36,268,000
• Market Cap: $12.57 billion
• Optionable: Optionable
• Beta: 0.88